<DOC>
	<DOCNO>NCT00242203</DOCNO>
	<brief_summary>This study design evaluate impact Zometa clearance bone marrow micrometastases ; protective effect chemotherapy-induced loss bone mineral density ; quality life woman undergo treatment locally advance breast cancer .</brief_summary>
	<brief_title>Evaluation Chemotherapy Prior Surgery With Without Zometa Women With Locally Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>Newly diagnose primary invasive ductal invasive lobular breast adenocarcinoma Tumor classify clinically large T2 ( 25 cm ) , T3 , T4 T N1 , N2 Prior malignancy : limit curatively treat basal squamous carcinoma skin history previous malignancy , treat &gt; 5 year disease free &gt; = 18 year age Normal leave ventricular function echocardiogram radioventriculogram Karnofsky Performance &gt; = 70 No evidence distant metastasis present CT , Bone scan , physical exam If bone scan CT scan demonstrate indeterminate lesion , nature lesion may clarify additional test PET MRI No current treatment Zometa bisphosphonates No serious functional disorder liver kidney : Serum Creatinine &lt; =2 ALT/AST/ALK Phos &lt; = 1.5 x upper limit institutional normal . Bili &lt; = 1.5 x upper limit institutional normal . Currently pregnant</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Neoadjuvant</keyword>
	<keyword>Micrometastasis</keyword>
</DOC>